Comparing Once Daily Versus Twice Daily Aspirin in Adults with High-risk Myeloproliferative Neoplasms and Aspirin Resistance

What this Trial Is About

Researchers are comparing the long-term effects of taking aspirin once daily versus twice daily in patients with high-risk myeloproliferative neoplasms MPN who show laboratory aspirin resistance. This prospective randomized study aims to see if increasing the aspirin dose helps reduce the risk of blood clots, as it is not known if doubling the dose always corrects aspirin resistance or prevents clotting events. The study includes adults with Philadelphia-negative MPN who already take aspirin but have aspirin resistance confirmed by platelet function tests. Participants are randomly assigned to receive either 81 mg of aspirin once daily or 81 mg twice daily. Platelet function testing using the LTA method will be repeated at one and six months after starting the assigned aspirin regimen to assess aspirin resistance. Additionally, a PFA200 test is performed at enrollment for comparison. The study will record clinical thrombosis events and any side effects related to aspirin use over at least two years. During the study, participants will undergo platelet function testing at set intervals and will be monitored for signs of blood clots, bleeding complications, and any adverse effects from aspirin. Researchers will analyze and compare the outcomes between the two aspirin dosing groups. Follow-up will continue for at least two years to gather comprehensive data on the incidence of thrombotic events and safety.

Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance